Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

Phase 0 Completed 10 enrolled Austin Neuromuscular Center Alnylam Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of patisiran in patients with wtATTR amyloidosis and symptomatic polyneuropathy by evaluating the effect on neurologic impairment and quality of life.

Timeline

Start: 2022-08-03
Primary completion: 2026-04-01
Completion: 2026-04-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Patisiran	Small interfering RNA (siRNA)	0.3 mg/kg	Intravenous

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

Summary

Timeline

Drugs

Indications